Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule designed as an inhibitor of beta-lactamase enzymes. Beta-lactamases are bacterial enzymes that confer resistance to beta-lactam antibiotics (such as penicillins and cephalosporins) by hydrolyzing the antibiotic's beta-lactam ring. The compound acts by binding to and inhibiting the activity of class C (AmpC) serine beta-lactamases, thereby restoring or enhancing the efficacy of beta-lactam antibiotics against resistant bacteria. It has been studied structurally in complex with SHV-type and Enterobacter cloacae GC1 class C beta-lactamases[4][5][7]. The molecule is experimental and not approved for clinical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-(4-carbamoyl-1-carboxy-2-methylsulfonyl-buta-1,3-dienylamino)-indolizine-2-carboxylic acid.